Latest News

First-half 2026 hepatology highlights include FDA approvals, hepatitis B and D advances, MASH progress, and AATD gene editing.

The supplemental New Drug Application for Arcutis’ roflumilast cream 0.05% (Zoryve) is for mild to moderate atopic dermatitis in those down to 3 months.

This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.

New Phase 3 COMP006 data show durable MADRS improvement in treatment-resistant depression following two doses of synthetic psilocybin.

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

The FDA granted accelerated approval to atacicept to reduce proteinuria in adults with primary IgAN at risk for disease progression

Frieden discusses somatic mutations driving vascular malformations and how repurposed cancer therapies like alpelisib and sirolimus are changing care.

FDA grants Priority Review to Agios’ mitapivat sNDA for sickle cell disease, with a PDUFA date set for November 1, 2026.

Catch up on Q2 hepatology headlines, including the historic FDA approval of bulevirtide for hepatitis delta, new data on bepirovirsen for HBV, and more.

This new analysis indirectly compares the clinical efficacy of risankizumab and icotrokinra in adults living with moderate-to-severe plaque psoriasis.

Catch up on the latest in hepatology, from bulevirtide’s FDA approval for hepatitis delta to expert perspectives on new and emerging therapies in PBC, PSC, and MASLD.

Here are 7 of the biggest nephrology stories from Q2 of 2026!

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.

Phase 3 RAPIDe-3 data show rapid, sustained relief of hereditary angioedema attacks; PDUFA date set for April 23, 2027.

June 2026 pulmonology news includes conversations with experts at the ATS and APAPP conferences, and cytisinicline's CRL.

This interview segment from SDPA highlights insights on hormonal impacts on dermatology as well as other key highlights from sessions at the meeting.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.